Ferritin Vaccine Platform for Animal and Zoonotic Viruses.

Sohrab Ahmadivand, Robert Fux, Dušan Palić
Author Information
  1. Sohrab Ahmadivand: Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, 80539 Munich, Germany. ORCID
  2. Robert Fux: Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, 80539 Munich, Germany. ORCID
  3. Dušan Palić: Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, 80539 Munich, Germany. ORCID

Abstract

Viral infections in animals continue to pose a significant challenge, affecting livestock health, welfare, and food safety, and, in the case of zoonotic viruses, threatening global public health. The control of viral diseases currently relies on conventional approaches such as inactivated or attenuated vaccines produced via platforms with inherent limitations. Self-assembling ferritin nanocages represent a novel vaccine platform that has been utilized for several viruses, some of which are currently undergoing human clinical trials. Experimental evidence also supports the potential of this platform for developing commercial vaccines for veterinary viruses. In addition to improved stability and immunogenicity, ferritin-based vaccines are safe and DIVA-compatible, and can be rapidly deployed in response to emerging epidemics or pandemics. This review discusses the structural and functional properties of ferritin proteins, followed by an overview of the design and production of ferritin-based vaccines, the mechanisms of immune responses, and their applications in developing vaccines against animal and zoonotic viruses.

Keywords

References

  1. J Virol. 2002 May;76(9):4241-50 [PMID: 11932389]
  2. Dose Response. 2016 Feb 26;14(1):1559325816632102 [PMID: 26977139]
  3. Vaccines (Basel). 2024 Jun 05;12(6): [PMID: 38932358]
  4. Science. 2019 Feb 8;363(6427):649-654 [PMID: 30573546]
  5. Methods Mol Biol. 2016;1349:1-24 [PMID: 26458826]
  6. JCI Insight. 2020 May 21;5(10): [PMID: 32434990]
  7. Viruses. 2022 Nov 03;14(11): [PMID: 36366541]
  8. EFSA J. 2023 Dec 12;21(12):e8442 [PMID: 38089471]
  9. Front Immunol. 2020 Jun 09;11:1100 [PMID: 32582186]
  10. Viruses. 2024 Jun 20;16(6): [PMID: 38932282]
  11. Virus Res. 2017 Feb 2;229:17-23 [PMID: 28012997]
  12. Vet Pathol. 1974;11(4):301-12 [PMID: 4156617]
  13. NPJ Vaccines. 2021 Dec 13;6(1):151 [PMID: 34903722]
  14. Arch Virol. 2021 Nov;166(11):2975-2988 [PMID: 34524535]
  15. Sci Rep. 2020 Oct 23;10(1):18149 [PMID: 33097791]
  16. Sci Rep. 2016 Oct 31;6:36298 [PMID: 27796362]
  17. Microb Pathog. 2020 Dec;149:104321 [PMID: 32534183]
  18. Bioconjug Chem. 2011 Mar 16;22(3):376-87 [PMID: 21355575]
  19. Biochemistry. 2023 Jan 17;62(2):292-299 [PMID: 35960597]
  20. Front Immunol. 2024 Mar 14;15:1328266 [PMID: 38550592]
  21. mBio. 2019 Feb 26;10(1): [PMID: 30808695]
  22. Small. 2024 Aug;20(31):e2310913 [PMID: 38726952]
  23. Front Cell Infect Microbiol. 2023 Jun 22;13:1216364 [PMID: 37424789]
  24. Fish Shellfish Immunol. 2019 Jul;90:210-214 [PMID: 31039441]
  25. Vaccines (Basel). 2021 Jan 13;9(1): [PMID: 33451123]
  26. Vaccine. 2020 Jul 31;38(35):5647-5652 [PMID: 32624251]
  27. J Biol Inorg Chem. 2007 Jun;12(5):615-30 [PMID: 17541801]
  28. Microbes Infect. 2002 Sep;4(11):1183-92 [PMID: 12361919]
  29. NPJ Vaccines. 2021 May 13;6(1):70 [PMID: 33986287]
  30. Animals (Basel). 2023 Dec 09;13(24): [PMID: 38136839]
  31. Nat Nanotechnol. 2020 May;15(5):406-416 [PMID: 32123380]
  32. Virus Res. 2010 Dec;154(1-2):86-97 [PMID: 20692304]
  33. Nat Rev Dis Primers. 2018 Jun 28;4(1):3 [PMID: 29955068]
  34. Clin Microbiol Rev. 2013 Jul;26(3):476-92 [PMID: 23824369]
  35. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7 [PMID: 22366317]
  36. Pharmaceutics. 2021 Oct 05;13(10): [PMID: 34683914]
  37. Pharmaceuticals (Basel). 2018 Nov 13;11(4): [PMID: 30428583]
  38. Front Immunol. 2024 May 21;15:1361323 [PMID: 38835763]
  39. Vaccines (Basel). 2023 Mar 05;11(3): [PMID: 36992179]
  40. Vaccines (Basel). 2021 May 28;9(6): [PMID: 34071482]
  41. Viruses. 2021 Aug 04;13(8): [PMID: 34452407]
  42. Dev Comp Immunol. 2017 Sep;74:178-189 [PMID: 28479343]
  43. Vaccines (Basel). 2023 Apr 10;11(4): [PMID: 37112733]
  44. Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2316960121 [PMID: 38319964]
  45. Front Cell Infect Microbiol. 2013 Mar 25;3:13 [PMID: 23532930]
  46. Virology. 2021 Jan 2;552:112-120 [PMID: 33152628]
  47. Int J Mol Sci. 2019 Apr 30;20(9): [PMID: 31052154]
  48. Pathogens. 2020 Sep 24;9(10): [PMID: 32987803]
  49. ACS Nano. 2024 Jan 30;18(4):3382-3396 [PMID: 38237058]
  50. J Virol. 2023 Nov 30;97(11):e0095823 [PMID: 37846983]
  51. Nat Med. 2015 Sep;21(9):1065-70 [PMID: 26301691]
  52. Viruses. 2021 Mar 10;13(3): [PMID: 33802100]
  53. Int J Mol Sci. 2011;12(8):5406-21 [PMID: 21954367]
  54. Front Immunol. 2022 Jul 19;13:930631 [PMID: 35958565]
  55. Viruses. 2022 Feb 15;14(2): [PMID: 35215994]
  56. J Biol Inorg Chem. 2016 Mar;21(1):13-28 [PMID: 26825805]
  57. JACS Au. 2023 May 04;3(5):1267-1283 [PMID: 37234110]
  58. Hum Vaccin Immunother. 2024 Dec 31;20(1):2347019 [PMID: 38807261]
  59. Front Immunol. 2024 Jan 29;15:1346512 [PMID: 38352881]
  60. NPJ Vaccines. 2023 Mar 18;8(1):43 [PMID: 36934088]
  61. Front Immunol. 2024 Jun 06;15:1387811 [PMID: 38911870]
  62. Nat Med. 2022 Feb;28(2):383-391 [PMID: 35115706]
  63. J Biochem. 2006 May;139(5):881-5 [PMID: 16751596]
  64. Front Immunol. 2018 Jun 26;9:1432 [PMID: 29997617]
  65. Vaccines (Basel). 2021 Apr 16;9(4): [PMID: 33923573]
  66. Nature. 2013 Jul 4;499(7456):102-6 [PMID: 23698367]
  67. Eur J Immunol. 2008 May;38(5):1404-13 [PMID: 18389478]
  68. Pathogens. 2023 Mar 01;12(3): [PMID: 36986312]
  69. Front Immunol. 2018 May 17;9:1093 [PMID: 29868035]
  70. Mol Immunol. 2018 Feb;94:61-67 [PMID: 29274924]
  71. J Nanobiotechnology. 2022 Jan 10;20(1):32 [PMID: 35012571]
  72. Annu Rev Anim Biosci. 2016;4:129-54 [PMID: 26646630]
  73. Nanomedicine. 2016 Aug;12(6):1735-45 [PMID: 27071333]
  74. Int J Biol Macromol. 2023 Jan 1;224:319-343 [PMID: 36280176]
  75. Expert Rev Vaccines. 2009 Apr;8(4):499-508 [PMID: 19348565]
  76. Int J Pharm. 2005 Jul 25;298(2):315-22 [PMID: 15961266]

Word Cloud

Created with Highcharts 10.0.0vaccinesvirusesferritinhealthzoonoticcurrentlyplatformdevelopingveterinaryferritin-basedViralinfectionsanimalscontinueposesignificantchallengeaffectinglivestockwelfarefoodsafetycasethreateningglobalpubliccontrolviraldiseasesreliesconventionalapproachesinactivatedattenuatedproducedviaplatformsinherentlimitationsSelf-assemblingnanocagesrepresentnovelvaccineutilizedseveralundergoinghumanclinicaltrialsExperimentalevidencealsosupportspotentialcommercialadditionimprovedstabilityimmunogenicitysafeDIVA-compatiblecanrapidlydeployedresponseemergingepidemicspandemicsreviewdiscussesstructuralfunctionalpropertiesproteinsfollowedoverviewdesignproductionmechanismsimmuneresponsesapplicationsanimalFerritinVaccinePlatformAnimalZoonoticVirusesself-assemblingproteinzoonoses

Similar Articles

Cited By